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b. Your role on project: Collaborating Investigator on Project #2 % Effort: 10% 
c. Dates and costs of entire project: 1 April 1993-31 March 1998 $597,671 (total) 
d. Dates and costs current year 1 April 1993 - 31 March 1994 $106,862 (total) 
e. Specific aims of project: This project elucidates the effects of sickle 
erythrocytes on endothelial cell structure and function. Specifically the 
influence of sickle cells on endothelial cell viability, morphology, growth factor 
secretion, and thrombogenicity is being investigated. These studies are aimed at 
determining the role of sickle erythrocyte membranes in vascular pathologies, 
particularly those associated with large vessel pathologies not likely associated 
with sickle cell adherence and microvascular occlusion. Dr. Wick , as a co-
investigator draws 10% salary from this grant and contributes 10% effort. 
f. Describe budgetary and scientific overlap: None. 
g. Describe adjustments you will make if the present application is funded 
(budget, % effort, aims, etc.): None 
2a. Source and Identifying Number: NIH-NRSA NIGMS GM08433 
P.I. Robert M. Nerem, Ph.D. Professor, School of Mechanical Engineering, Georgia 
Tech 
Title: Cellular Engineering Training Grant 
b. Your role on project: Collaborating Faculty 
% Effort: 0% 
c. Dates and costs of entire project: 	$339,208 (26 September 1991 - 31 August 
1995) 
d. Dates and costs current year: 1 September 1993 - 31 August 1994 
e. Specific aims of project: This project provides funds for 4 predoctoral 
students studying Cellular Engineering. Dr. Wick supervises one of these students 
working on sickle cell/endothelial cell interactions. 
f. Describe budgetary and scientific overlap: None. 
g. Describe adjustments you will make if the present application is funded 
(budget, % effort, aims, etc.): None. 
3a.Source and Identifying Number: The Whitaker Foundation 
P.I. Robert M. Nerem, Ph.D. Professor, School of Mechanical Engineering, Georgia 
Tech 
Title: Biomedical Engineering Education: An Interdisciplinary Tissue Engineering 
Education and Research Program 
b. Your role on project: Participating faculty 
% Effort: 0% 
c. Dates and costs of entire project: 	$3,000,000 (1 September 1993 - 31 August 
1996) 
d. Dates and costs current year: $1,000,000 (1 September 1993 - 31 August 1994) 
e. Specific aims of project: This grant provides funds for laboratory space 
renovation, the hiring of six new faculty in Tissue Engineering, and a limited 
number of graduate student stipends. 
f. Describe budgetary and scientific overlap: None. 
g. Describe adjustments you will make if the present application is funded 
(budget, % effort, aims, etc.): None. 
4a. Source and Identifying Number: NSF 	 BCS-9111761 
P.I. Robert M. Nerem, Ph.D. Professor, School of Mechanical Engineering, Georgia 
Tech 
Title: Reconstitution of a Vascular Graft 
b. Your role on project: Co-investigator 
% Effort: 5% 
c. Dates and costs of entire project: 	$535,732 (1 September 1991 - 28 February 
1995) 
d. Dates and costs current year: $150,000 (1 September 1993 - 31 August 1994) 
o. Specific aims of project: Dr. Wick will evaluate the thrombogenicity of tissue 
engineered blood vessels developed in Dr. Nerem's lab. 
f. Describe budgetary and scientific overlap: None. Dr. Wick will spend 
approximately $15,000 of this grant in the final year to investigate platelet 
adherence. 
g. Describe adjustments you will make if the present application is funded 
(budget, % effort, aims, etc.): None. 
Pending Applications 
la.Source and Identifying Number: NSF-Engineering Research Center 
P.I. Robert M. Nerem, Ph.D. Professor, School of Mechanical Engineering, Georgia 
Tech 
Title: A Research Center for the Engineering of Living Tissues 
b. Your rola on project: Participating faculty 
% Effort: 5% 
c. Dates and costs of entire project: 	$11,048,605 (1 September 1994 - 31 
August 1999) 
d. Dates and costs current year: 
e. Specific aims of project: This grant application is to develop a center at 
Georgia Tech to develop research and new technology for the engineering of new 
cardiovascular devices. 
f. Describe budgetary and scientific overlap: None. 
g. Describe adjustments you will make if the present application is funded 
(budget, % effort, aims, etc.): None. 
INTERACTIONS 
1. Specific Aims 
The tendency for hemoglobin SS to polymerize at low oxygen tension is 
assumed to dominate sickle cell pathology. Since morphological sickling is 
delayed after hemoglobin deoxygenation, factors which delay erythrocyte 
microcirculatory transit are likely antecedents to microvascular occlusion, 
ischemic tissue damage, and pain episodes characteristic of sickle cell 
anemia. Our central hypothesis is that sickle erythrocyte adherence to 
microvascular endothelium delays erythrocyte microcirculatory transit 
permitting intracapillary erythrocyte sickling leading to complete occlusion 
(1). Adherence may be affected by secondary perturbations in hematological 
parameters such as infection which can activate the endothelium to favor 
adherence. 	Our data clearly indicate that plasma, red cell and endothelial 
cell factors, and hemodynamics all likely contribute to adherence and 
occlusion in vivo (2-7). Our specific aims for this project are to (i) 
demonstrate that infection induces endothelial cell alterations which increase 
sickle erythrocyte adherence, (ii) quantify the expression of endothelial cell 
ICAM-1, VCAM-1, and E-selectin after exposure to sickle erythrocytes and 
determine the mechanism of sickle red cell adherence to erythrocyte-activated 
endothelium, (iii) develop novel adhesion systems to study the 
interrelationship between adherence, endothelial cell function, and fluid 
mechanics under conditions which closely mimic those in vivo. It is becoming 
clear that red cells, white cells, endothelium and hemodynamics interact to 
alter cellular function. These alterations are exacerbated by the presence of 
sickle hemoglobin. The long-term goal of this research, in close 
collaboration with Projects 2,3, and 4 is to elucidate the role of red cells, 
endothelium, and hemodynamics as well as the extent to which the thrombotic 
and immune systems participate in sickle cell vascular complications. 
2. Studies and Results 
Elucidate the role of infection in sickle cell vascular complications 
Anecdotal evidence suggests that infection may initiate or participate 
in vascular complications associated with sickle cell anemia (8-10) although 
the possible relationship between infection and vascular complications in 
sickle cell anemia has not yet been established. Since sickle reticulocytes 
adhere to cytokine activated (e.g. VCAM-1 expressing [14]) endothelium via a 
VCAM-1/a401-dependent mechanism (11) and double-stranded RNA (a model for 
viral infection [12]) induces endothelial cell expression of VCAM-1 (13), we 
hypothesized that double-stranded RNA induction of endothelial VCAM-1 would 
increase sickle erythrocyte adherence via a similar mechanism. When 
endothelial cells were incubated with the synthetic double stranded RNA poly 
(I:C) (polyinosinic acid:polycytidilic acid) endothelial cell VCAM-1 
expression increased (Fig 1) leading to a concomitant increase in sickle, but 
not normal erythrocytes (Fig 2) under continuous flow conditions at a shear 
stress of 1.0 dyne/cm2 . This increase in VCAM-1 expression and adherence was 
not observed when endothelial cells were incubated with single stranded RNA 
(Poly (I)) (Figure 2). Preincubation of endothelium with anti-VCAM-1 antibody 
or erythrocytes with anti -adil antibody inhibited Poly (I:C) induced sickle 
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erythrocyte adherence by 100% and 56%, respectively. Neither anti-glycophorin 
on the erythrocytes or anti-ICAM-1 on the endothelium inhibited the adherence 
induced by Poly (I:C) (not shown). 
Figure 1. Poly (I:C) induces VCAM-1 
expression. ELISA data (15) after 
indicated incubation for 22 hours. 
Data are representative experiment 
perfcrmed on four separate occasions. 
Figure 2. Sickle erythrocytes adhere to poly 
(I:C) stimulated endothelium. Data are 
meantS.D. of experiments with blood from 11 
homozygous, asymptomatic sickle patients and 
5 normal donors. 
Figure 3. Anti-VCAM-1 or anti k. antibody inhibits sickle erythrocyte adherence to 
Poly (I:C) activated endothelium. Data are two representative patients of five studied to dat( 
Quantification of expression of endothelial cell adhesion molecules induced by 
sickle erythrocytes 
The above data suggest that a variety of factors can stimulate 
endothelial cell adhesivity and increased sickle erythrocyte adherence. 
Others have demonstrated that some vascular lesions in sickle cell anemia are 
localized to large cerebral arteries and lead to increased incidence of large 
vessel complications, including stroke and other neurological complications, 
in sickle patients (16-18). Clearly these lesions are not the result of 
microvascular occlusion. Since these clinical complications can apparently be 
eliminated with transfusion therapy, we hypothesize that sickle erythrocyte 
membrane abnormalities can directly activate endothelium, leading to increased 
red cell (and possibly white cell or platelet) adherence. As can be seen in 
Figures 4-6, incubation of cultured human umbilical vein endothelium with 
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Figure 4. Time course of VCAM-1 
upregulation. Data are meantSEM of 
indicated number of experiments. 
Washed sickle or normal erythrocytes were 
incubated at 1% hematocrit with confluent 
monolayers of endothelium for the indicate( 
times. 
Figure 6. Time course of ICAK-1 
	
Figure 7. Polymyxin B does not 
upregulation. 	 inhibit sickle erythrocyte-induced 
endothelial cell adhesion molecule 
expression. 
The sickle erythrocyte induction of endothelial cell adhesion molecule 
expression is not related to possible bacterial contamination since polymyxin 
B, a potent inhibitor of lipopolysaccharide induced VCAM-1 expression, had no 
effect on the observed phenomena (Figure 7). 
Finally, since sickle erythrocytes can induce endothelial cell VCAM-1 
(and other cell adhesion molecule expression), studies were undertaken 
determine whether endothelium exposed to sickle red cells could support higher 
adherence of sickle erythrocytes. For these studies, human umbilical vein 
endothelial cells were incubated with washed sickle erythrocytes at 1% 
hematocrit for 8 hours. Then, the sickle red cells were removed from the 
endothelial cells by washing for 20 minutes at 1 dyne/cm 2 . Adherence assays 
were then performed with fresh washed erythrocytes from the same donor. As 
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can be seen in Figure 8, sickle red cell adherence was elevated on endothelial 
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Figure 8. Red cell sonication inhibits 
sickle red cell induced VCAM-1 expression. 
Endothelial cells were incubated with 
sonicated or intact washed sickle or 
normal red cells for 8 hours and 
protein expression was determined by ELISA 
Figure 9. Sickle erythrocytes are more 
adherent to endothelial cell monolayers after 
prolonged stimulation with sickle red cells. 
Results are from one experiment. 
sickle cell 
and thus establish a possible link between viral infection and sickle cell 
adherence 
These investigations are the result of collaborations with Project #2. 
Additional details of the effects of sickle cells are presented in that 
progress report as well as details related to future investigations. Since 
project #1 is primarily related to sickle red cell/endothelial cell adhesion, 
future studies along these lines will be primarily related to the effect of 
sickle cells on endothelial cell adhesivity. 
3. Significance 
Double stranded RNA induces sickle cell adherence. 
Previous studies suggest that pain events in sickle cell patients may by 
initiated or exacerbated by infection, however the link between infection and 
vascular complications in sickle cell anemia is not clear. Many pathogenic 
viruses, including rhinoviruses, influenza viruses, measles viruses, coxsackie 
viruses, enteroviruses, and flaviviruses exist as double stranded RNA viruses 
or replicate through double stranded RNA intermediates (19). Recent studies 
have demonstrated that double stranded RNA illicits many of the pathogenic 
complications in animals as the intact virus, suggesting that double stranded 
RNA may be a reasonable model for viral infection (12). The data of Figures 
1-3 indicating that double stranded RNA specifically induces endothelial cell 
VCAM-1 expression and sickle erythrocyte adherence via a vcAm-i/a40 1 
interaction suggests that viral infection in sickle cell disease may initiate 
microvascular occlusion by promoting sickle red cell adherence to endothelium 
in vivo. Future studies, in collaboration with Dr. Margaret K. Offermann, 
Department of Hematology/Oncology, School of Medicine, Emory University School 
of Medicine will focus on the mechanism of double stranded RNA induced VCAM-1 
induction and whether intact viruses increase sickle red cell adherence to 
endothelium (20) in a manner similar to that induced by double stranded RNA. 
Direct activation of endothelium by sickle erythrocytes 
4. Plana 
In general, we do not anticipate significant deviation from the original 
proposal. 
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5. Human Subjects 
a. General Guidelines 
i. Proposed Use 
Patients with sickle-cell syndromes (HbSS, HbSC, HbS b-thalassemia) not 
receiving anticoagulant therapy and without evidence of pregnancy, obvious 
infection, thromboembolic disease or liver disease will be eligible for this 
study. Patients will be studied once in pain crisis and twice during 
asymptomatic periods. An age and sex matched population of normal black 
individuals will serve as a control population. Approximately twenty patients 
and twenty control subjects, aged eighteen or older, will be studied annually. 
Ten milliliters of blood will be drawn by venipuncture for each experiment. 
ii. Specimen Usage 
None of the data from the experiments will be used for diagnosis or 
treatment of specific individuals. 
iii. Patient Recruitment 
Patients from the Sickle Cell Center or the in-patient service at Grady 
Memorial Hospital, Atlanta, GA and hospital staff will be recruited by Dr. 
James R. Eckman. Subjects will agree to participate in this study by signing 
a consent form approved by Georgia Tech and Emory University School of 
Medicine IRBs. The consent form explains the nature of the study, the details 
of blood collection, risks associated with drawing blood, the availability of 
personnel to discuss the results of the study, the assurance of anonymity, and 
the ability to withdraw from the study at any time without penalty or loss of 
benefits. 
iv Potential Risks 
The risks of drawing blood are minimal and include slight pain, 
bruising, and infection at the site of puncture. No viable alternative for 
drawing human blood exists. 
v. Procedures to Minimize Risk 
Patient confidentiality will be ensured by assigning a code to each 
patient studied (SS1, AA1 for sickle and normal donor, respectively) to be 
used when all data is reported. Blood will be drawn at Grady Hospital under 
the supervision of Dr. James R. Eckman, director of the Sickle Cell Clinic. 
Dr. Eckman will be available to answer questions and to arrange for emergency 
medical care if a medical problem develops during the course of this study. 
vi. Justification 
The risk of blood drawing is minimal compared to potential benefits of a 
better understanding of clotting abnormalities in sickle cell syndromes and 
their relationship to pain crisis. 
b. Gender and Minority Inclusions 
Study subjects will be patients diagnosed with sickle cell syndromes as 
defined above. These patients will primarily be of African descent, however 
no patients will be included or excluded on the basis of race. The study 
population will consist of approximately equal numbers of men and women. 
Exclusion criteria will be solely based on medical criteria as described 
above. Control subjects (volunteers without hemoglobinopathies) will be age, 
sex, and race-matched. These volunteers are recruited from the hospital staff 
at Grady Memorial Hospital in Atlanta. 
6. Vertebrate Animals 
None. 
7. Publications (from this project) 
a. Journal Articles 
b. Abstracts and Meetina Presentations 
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attachment factors 
Monoclonal antibodies, synthetic pestides 
Disposable supplies (culture flasks, pipets, fillters, 
gloves, etc.) 
Elisa Reagents, FRCS Supplies 
TRAVEL 







PATIENT CARE COSTS INPATIENT 	NONE 
OUTPATIENT NoNE 
ALTERATIONS AND RENOVATIONS (Itemize by category) 
NONE 
OTHER EXPENSES (Itemize by category) 
Publication fees, artwork, photography 	 $1,500 
Shop charges for flow loop manufacture $ 900 $ 2,400 
SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD  
feitt$0561MtrofiW:ekSe5664x1195d6c 
DIRECT COSTS 	s 86,439  
INDIRECT COSTS S 34,576 (40% of Direct) 
TOTAL -Ow 
TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (Enter on Page 1, Item 10a) S  Wif7t gi9t0 




SUPPLEMENTAL INFORMATION REGARDING ITEMS IN THE PROPOSED BUDGET FOR THE NEXT PERIOD WHICH REQUIRE 
EXPLANATION OR JUSTIFICATION. (See instructions) 
Personnels Fringe benefits are 24.7% of salary. 
Principal Investiaator - Dr. Timothy M. Wick, Ph.D.: Funding is requested for the 
Principal Investigator to provide time to organize the study, coordinate in vitro 
investigations with clinical studies, perform experiments, analyze data, prepare 
manuscripts, hold regular laboratory meetings of the investigators, and develop 
progress reports. It is estimated that 20% of Dr. Wick's time will be devoted to 
these tasks related to the Project #1 of the Georgia Comprehensive Sickle Cell 
Center. 
Graduate Student - Paula Smolinski: 	Ms. Smolinski has been working in the 
laboratory since September 1992. She is responsible for much of the new data 
presented in the Results section. Specifically, Ms. Smolinski has performed the 
investigations demonstrating that infection of endothelial cells with double 
stranded RNA or a double stranded RNA virus increases sickle cell adherence via 
0401/VCAM- 1. She has also performed the detachment assays and will continue to be 
responsible for measuring the strength of sickle cell adherence via the various 
pathways. Ms. Smolinski will devote 100% of her effort to this project. 
Graduate Student - Richard Montez: Mr. Montez has been working in the lab since 
December 1993. He has developed the cone-and-plate viscometer shown in the Progress 
Report and the protocols for measuring the kinetics of sickle cell adherence 
described in the present Continuation Application. Mr. Montez will devote 100% of 
his effort to this project. 
Graduate Student - Marena Brown: Ms. Brown has been working in the lab since Summer 
of 1992. Ms. Brown is investigating the effect of plasma components in sickle blood 
(such as leukocytes and cytokines) on the activation of endothelial cells in vivo. 
She is currently working to identify the specific component(s) in sickle blood that 
induce endothelial cell expression of cell adhesion molecules. Ms. Brown is 
currently supported by other funds and no support is being requested for her from 
this application. 
Cell Culture Technician: This person is responsible for maintaining endothelial 
cell cultures. This entails harvesting cells from tissues or procuring from other 
sources; maintaining viable cell stocks; and providing cells for use in adherence 
assays and ELISAs. This person is required because we are using endothelial cells 
from different sources (e.g. veins, arteries, and microvessels) each of which has 
exacting and different culture requirements. Having one person as an expert in 
endothelial cell culture is invaluable to efficient and reproducible progress on 




CURRENT BUDGET PERIOD 	
1 April 1995 
	
31 March 1996 
The following pertains to your CURRENT PHS budget. This information may be used in determining the amount of support for the NEXT 
budget period. 









EXPLAIN ANY SIGNIFICANT ESTIMATED 
UNOBLIGATED BALANCE IN COLUMN 2 
(3) 
TOTAL DIRECT COSTS $ 73,996 0 
INDIRECT COSTS (As provided) $ 29,440 0 
$103,592 0 TOTALS 
Use Continuation Pages if necessary) (Form Page 3) Page PHS•2590 (Rev. 9/91) 
Supplies: Tissue culture costs are based upon current performance of 2 flow 
experiments per week as well as current usage and costs. Media, serum, growth 
factors, buffers, and other chemicals as well as plasticware, glassware, and gloves 
are required for cell cultures and adhesion assays. Monoclonal antibodies to 
adhesion receptors will be used to identify receptors that are necessary for sickle 
erythrocyte adhesion to endothelium. 
Travel: Funds are requested for Dr. Wick or an associate to attend ASH and the 
annual Meeting of the Sickle Cell Disease Program to present research and interact 
with colleagues interested in similar and related areas of hematology and sickle 
cell anemia. 
Other ixpenses: Funds are requested to cover the cost photocopying, medical 
illustrations and page costs for presentations and publications. Machine shop 
charges are required to construct new adhesion systems. 
GRANT NUMBER:  1P01 48482-03 
BIOGRAPHICAL SKETCH 
Give the following information for all new key personnel, consultants, and collaborators. 




Timothy M. Wick 
	
Associate Professor 
. her initial professional education, such as nursing, and include postdoctoral training.) ---- 	— 	, 	. 
INSTITUTION AND LOCATION DEGREE 
YEAR 
CONFERRED 
FIELD OF STUDY 
University of Colorado, Boulder, OD B.S. 1983 Chemical Engineering 
Rice University, Houston, TX Ph.D. 1988 Chemical Engineering 
Rice University, Houston, TX Post -doc 1988 Chemical Engineering 
and Rinrhamiatry 
RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list, In chronological order, previous employment, ex-
perience, and honors. Key personnel include the principal investigator and any other individual who participate in the scientific development 
or execution of the project. Key personnel typically will include all individuals with doctoral or other professional degrees but in some pro-
jects will include individuals at the masters or baccalaureate level provided they contribute in a substantive way to the scientific development 
or execution of the project. Include present membership on any Federal Government public advisory committee. List, in chronological order, 
the titles, all authors, and complete references to all publications during the past three years and to representative earlier publications perti-
nent to this application. DO NOT EXCEED TWO PAGES. 
Professional 2xperience 
7/94-present Associate Professor, School of Chemical Engineering, Georgia Institute 
of Technology, Atlanta, GA 
7/94-present Associate Professor, School of Mechanical Engineering, Georgia Tech, 
Atlanta, GA 
4/93-6/94 	Assistant Professor, School of Mechanical Engineering, Georgia Tech, 
Atlanta, GA 
9/88-6/94 	Assistant Professor, School of Chemical Engineering, Georgia Institute 
of Technology, Atlanta, GA 
2/88-9/88 	Post-doctoral Research Associate, Department of Chemical Engineering, 
Rice University, Houston, TX 
2/88-9/88 	Post-doctoral Research Associate, Department of Chemical Engineering, 
Rice University, Houston, TX 
Honors and Awards 
1993 Ad-Hoc Reviewer. Academic Research Initiation Grants Program, North Carolina 
Biotechnology Center. 
1993 Ad-Hoc Reviewer. Biomaterials Panel, Biomedical Engineering and Research to 
Aid Persons with Disabilities Program, National Science Foundation . 
1993 Member. Special Emphasis Panel, NIH Collaborative Projects (ROls) on Minority 
Health. 
1993 Reviewer. 	Biomedical Engineering Society 1993 Graduate Student Awards 
Committee. 
1993 Outstanding Chemical Engineering Professor. Awarded by the Student Chapter of 
Omega Chi Epsilon. 
1992 Lilly Foundation Teaching Fellowship. 
1991 Young Investigator Award Finalist. The 1991 World Congress on Medical Physics 
and Biomedical Engineering. 
1991 American Heart Association-Georgia Affiliate, Grant-In-Aid 
1991 The Whitaker Foundation, Biomedical Engineering Research Grant 
1991 NIH-First Independent Research and Transition (FIRST) Award 
1990 Du Pont Young Faculty Award 
1991 Du Pont Young Faculty Award 
1989 American Heart Association-Georgia Affiliate, Grant-In-Aid 
1987 Beecham Award for outstanding original research presented at annual meeting of 
the Southern Society for Clinical Investigation, the Southern Section of the 
AFCR and the Southern Society for Pediatric Research 
1986 Omega Chi Epsilon (National Chemical Engineering Honor Society) 
PHS 398/2590 (Rev. 9/91) 	 (Form Page 4) Page 
Original Articles 
1. Wick, T.M., J.L. Moake, M.M. Udden, S.G. Eskin, D.A. Sears and L.V. McIntire. 
'Unusually Large von Willebrand Factor Multimers Increase Adhesion of Sickle 
Erythrocytes to Endothelial Cells Under Controlled Flow.' journal of Clinical 
Investigation, 90:905-910 (1987). 
2. Wick, T.M., S.D. Doty, and R.M. Nerem. 'Influence of Fluid Mechanical Stresses 
on Vascular Cell Adhesion.' In: Biomechanical Transport Processes, F. Mosora, 
C. Caro, E. Krause, H. Schmid-Schonbein, C. Baquey, and R. Pelissier, eds, 
Plenum, New York, pp. 283-292, 1990. 
3. Wick, T.M. and V. Louis. 'Cytoadherence of Plasmodium falciparum-Infected 
Erythrocytes to Human Umbilical Vein and Human Dermal Microvascular Endothelial 
Cells under Shear Conditions.' Am J Tropical Med Hygiene 45: 578-586 (1991). 
4. Swerlick, R.A., K. Lee, T.M. Wick, and T.J. Lawley. 'Human Dermal Microvascular 
Endothelial but not Human Umbilical Vein Endothelial Cells Express CD36 In Vivo 
and In Vitro.' Journal of Immunoloav, 148:78-83 (1992). 
5. Yoganathan A.P., T.M. Wick, & H. Reul. 'The Influence of Flow Characteristics 
of Prosthetic Valves on Thrombus Formation.' In: Thrombosis. Embolism. and 
Bleeding, E.G. Butchart and E. Bodnar, eds, ICR Publishers, London, pp. 123-148, 
1992 
6. Wick, T.M. and V. Louis. 'Plasmodium fragile: Cytoadherence of Parasitized 
Rhesus Monkey Erythrocytes to Human Endothelial Cells under Shear Flow 
Conditions.' Zxperimental Parasitology, 74:228-231 (1992). 
7. Brittain, H.A., J.R. Eckman, and T.M. Wick. 'Sickle Erythrocyte Adherence to 
Large Vessel and Microvascular Endothelium under Physiologic Flow is 
Qualitatively Different.' J Lab Clin Med, 19:538-545 (1992). 
8. Wick, T.M., J.L. Moake, M.M. Udden, and L.V. McIntire. 'Unusually Large von 
Willebrand Factor Multimers Preferentially Promote Young Sickle and Non-sickle 
Erythrocyte Adhesion to Endothelial Cells,' Am J Hematoloav, 42:284-292 (1993). 
9. Johnson, J.K., R.A. Swerlick, P. Millet, K. Grady, T.M. Wick. 'Cytoadherence of 
Plasmodium fa/ciparum-Infected Erythrocytes to Microvascular Endothelium is 
Regulatable by Cytokines and Phorbol Ester,' IT Infect Dis, 167:698-703 (1993). 
10. Brittain, H.A., J.R. Eckman, R.J. Howard, and T.M. Wick. "Thrombospondin from 
Activated Platelets Promotes Sickle Erythrocyte Adherence to Human Microvascular 
Endothelium under Physiologic Flow: A Potential Role for Platelet 	Activation 
in Sickle Cell Vaso-occlusion,' Blood, 81:2137-2143 (1993). 
11. Flaherty, A.L. and T.M. Wick. 'Prolonged Contact with Blood Alters Surgical Gown 
Permeability,' The American Journal of Infection Control, 21:249-256 1993. 
12. Swerlick, R.A., J.R. Eckman, A. Kumar, M. Jeitler, and T.M. Wick. pa4E1-Integrin 
Expression on Sickle Reticulocytes: Vascular Cell Adhesion Molecule-l-Dependent 
Binding to Endothelium,' Blood, 92:1891-99 (1993). 
13. Wick, T.M., H.A. Brittain, R. Howard, and J.R. Eckman. 'Thrombospondin from 
Activated Platelets Promotes Sickle Erythrocyte Adherence to Human Microvascular 
Endothelial Cells via CD36 and integrin receptors,' In: Vascular Endothelium:  
Physiological Basis of Clinical Problems TI, J. Catravas, A. Callow, N. Gillis, 
U. Ryan, A. Mantovani, and M. Yacoub, eds, Plenum, New York, (In press) 1994. 
14. Smolinski, P.A., M.K. Offermann, J.R. Eckman, and T.M. Wick. 'Synthetic Double 
Stranded RNA Increases Sickle Red Blood Cell Adherence to Endothelium via a 
VCAM-1/VLA-4 Pathway,' Blood (In review). 
15. Gonzales, R. and T.M. Wick. 'The Dual Effect of Shear Stress in Regulating 
Monocyte Adherence to Vascular Endothelium,' Annals of Biomedical Enaineerina 
(In review). 
16. Kumar, A., R.A. Swerlick, J.R. Eckman, and T.M. Wick. 'Stimulation of Sickle 
Erythrocytes with Phorbol Ester Promotes Endothelial Adherence: A Novel 
Adherence Pathway involving Activated (1401 and Fibronectin,' Blood (In 
preparation). 
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a source  and Identifying no. NIH 1R29 HL44960 
  
P.I. T. M. Wigk 
 
   
Two  The Mechanism of Sickle Erthrocyte/Endothelial Adherence 
b. Your role on project Principal Investigator 	% Effort 50% 
C. Dates and costs of entire project  25 July 1991 - 30 June 1996 $349,992 (direct)  
d. Dates and costs of current year  1 July 1994 - 30 June 1995 	($70,539)  
cftedficaimmotimosct  (1) Characterize sickle erythrocyte adhesion to endothelium  
from different-vascular beds, (2) determine inter- and intra-patient variability  
in adhesion for patients in steady state and crisis, (3) identify plasma factors  
which promote adherence, (4) identify the role of agonists and vaso-active factors  
in adherence. The R29 research involves different graduate students and although  
complementary. is seuarate from the SCORE research.  
f. Describe scientific and budgetary overlap 	None  
g. Describe adjustments you will make if the present application is funded (budget, % effort, aims, etc.) 
None 
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significant delays In the review and/or funding of the application. 
Other support is defined as all funds or resources, whether Federal, non-Federal, or Institutional, available to the principal 
investigator/program director (and other key personnel named In the application) in direct support of their research endeavors through 
research or training grants, cooperative agreements, contracts, fellowships, gifts, prizes, and other means. 
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Name  Timothy M. Wick. Ph.D 
 
Active 	X 	Pending 	 None 
 
  
Source and identifying no. 	NIM 1P60 HL48482-01 Proiect 2 	P.I. J.R. Eckman 
Title Georgia Comprehensive Sickle Cell Center-Project #2  
b. Your role on project  Collaborating Investigator on Project 2  %Elton 	10%  
C. Dates and costs of entire project  1 April 1993 - 31 March 1998 $597.671 (total p jart 2)  
d. Dates and costs of current year 	1 Apri 1 1994 - 11 Marrh 199R $112,655  
Specific aims of project  This  project elucidates the effects of sickle erythrocytes on 
endothelial cell structure and function. These studies are aimed at elucidating 
the role of sickle erythrocyte membranes in sickle cell vascular pathology. 
Dr. Wick draws 10% salary from this project and contributes 10% effort. 
f. Describe scientific and budgetary ~lap  None 
g. Describe adjustments you will make If the present application is funded (budget, % effort, aims, etc.) 
None 
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Nam  Timothy M. Wick 
 
Active 	X 	Pending 	 None 
 
  
sAkumesnimemitorig nm  Allelix Biopharmaceuticals, Inc. 	pi T. Wick 
Tito Inhibition of Sickle Cell Adherence by CSVTCG Peptide 
b. Your role on project Principal Investigator % Effort 	5% 
 
 
   
c. Dates and costs of entire project 	1 September 1994 - 28 February 1995 $60.065 
d.DatisimdcoMsolcurrentywkr 	1 September 1994 - 28 Febru=y 1995 $60.065 
e. Specific alms of project  To determine whether the hexapepti rle rsvra; inh 'hi ts 
thrornbospondin-mediated sickle cell adherence to mi rrovasri 11 a-r ennothpii  
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None 
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Name  Timothy M. Wick, Ph.D. 
          
          
a. Source end identifying no 	The Whitaker Foundation 
    
PI R. Nerem 
 
     
Title  Biomedical Engineering Education: An interdisciplinary Tissue Engineering 
Education and Research Program 
b. Your role on project Participating Faculty 	% Effort 	0%  
C.Didesandamitsoferitimpoilmt 	1 September 1993 - 31 August 1996 (S3.000.000) 
d. Dates and costs of current year  1 September 1994 - 31 August 1995 (S1.000.000) 
e. Specific alms of project 	Renovate laboratory space. hire new faritity area nippn-rt 
a limited number of graduate students in tissue prIginepring 
1. Describe scientific and budgetary overlap 	*VIP 
g. Describe adjustments you will mike If the present application is funded (budget, % effort, aims, etc.) 
None 
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stndying re11n1ar Pnginpering_ nr_ Wirk snpervises nnp of these Ri-nrients 
who works on sickle cell/endothelial interactions. 
f. Describe scientific and budgetary overlap 	None  
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research or training grants, cooperative agreements, contracts, fellowships, gifts, prizes, and other means. 
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PI T. M. Wick 
  
Two  Blocade of Sickle Red Cell Binding by Anti-alpha4 Antibodies 
b. Your role on project Principal Investigator 	V6Effon 	0% 
c. Dates and costs of entire project 1 March 1995 - 28 February 1996 ($25,000 total', 
 
d. Dates and costs of current year 
 
1 March 1995 - 28 February 1996 ($25.000 total) 
  
a. Specific aims of project  To set up a micropipet assay system to measure the 
strength of blood cell adhesion to endothelium under various conditions. 
This is an equipment grant to provide hardware (pipet manipulators. 
microscope, video equipment) to set up the assay systen. 
f. Describe scientific and budgetary overlap None 
g. Describe adjustments you will make if the present application is funded (budget, % effort, Sims, etc.) 
None 
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a Source and identifying no. 	National Institutes of Health 	A. Lane 
Ilt4  Free Fatty Acids in Sickle Pulmonary Vascular Injury 
b. Your rote on project  Collaborator 
 
% Elton 	5% 
 
  
c. Dates and costs of entire project $876,937 
 
d. Dates and costs of current year 	$287, 371 (First year) 
a. Specific aims of project  Free fatty acids cause _pulmonaz7 vassii1aT inj,rry by 
1) increasing endothelial permeabilitx , leading to edema; 2) enhancing 
endothelial production of vaso-active substances; and 3) increasing 
adherence of sickle cells, platelets and neutrophils to endothelium. 
Dr. Wick will contribute to specific aim #3. 
1. Describe scientific and budgetary overlap 	None  
g. Describe adjustments you will make If the present application is funded (budget, % effort, aims, etc.) 
None 
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PROGRESS REPORT SUMMARY 
1P60 HL48482 
FROM 
PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR 
Janes R. Eckman, M.D.  
PERIOD COVERED BY THIS REPORT 
THROUGH 
APPLICANT ORGANIZATION 
Emory University School of Medicine 	 1 April 1994 
TITLE OF PROJECT (Repeat title shown in item 1 on first page) 
Georgia Camprehensive Sickle Cell Center - Project #1  
(SEE INSTRUCTIONS) 
31 March 1995 
1. Specific Aims 
The tendency for hemoglobin SS to polymerize at low oxygen tension is assumed to be 
the dominant factor in sickle cell pathology. Since morphological sickling is 
delayed after hemoglobin deoxygenation, factors which delay red cell 
microcirculatory transit are likely antecedents to microvascular occlusion, ischemic 
tissue damage, and pain episodes characteristic of sickle cell anemia. Our central 
hypothesis is that sickle erythrocyte adherence to microvascular endothelium delays 
erythrocyte microcirculatory transit. This partial obstruction allows for 
intracapillary red cell sickling leading to complete occlusion (1). Adherence may 
be affected by secondary perturbations in hematological parameters such as infection 
which can activate the endothelium, the red blood cells, or alter blood hemodynamics 
such that adherence is favored. Our data clearly indicate that plasma, red cell 
and endothelial cell factors as well as local hemodynamics all likely contribute to 
adherence and occlusion in vivo (2-8). Our specific aims for this project are to 
(i) demonstrate that infection induces endothelial alterations which increase sickle 
erythrocyte adherence to endothelium, (ii) identify the dominant adherence 
mechanism(s) in the plasma milieu, and (iii) develop novel adhesion systems to study 
the interrelationship between adherence, endothelial cell function, and fluid 
mechanics under conditions which more closely mimic those in vivo. 
It is becoming clear that red cells, white cells and the fluid mechanical 
environment interact with the endothelium in such a way as to alter cellular 
function. These alterations are exacerbated in sickle cell anemia because of the 
presence of sickle erythrocytes which induce a myriad of alterations in blood. The 
long-term goal of this research, in close collaboration with Projects 2,3, and 4 is 
to elucidate the role of not only red cells, endothelium, and hemodynamics in 
vascular complications associated with sickle cell anemia, but also to determine the 
extent, if any, to which the thrombolytic and immune systems participate in sickle 
cell vascular complications. 
2. Studies and Results 
Elucidate the role of viral infection in sickle cell adherence to endothelium 
We recently reported that sickle reticulocytes express the a4131 integrin 
complex and can bind to VCAM-1 on cytokine activated endothelium (6). Pain episodes 
are often associated with febrile events precipitated by viral or bacterial 
infection (9). Many different cell types, including endothelial, have the capacity 
to recognize and respond to double stranded RNA (10-12). Recent studies demonstrate 
that double stranded RNA (DS-RNA) induces cellular adhesion molecules, including 
VCAM-1, in endothelial cells (13). 
We hypothesized that DS-RNA or DS-RNA viruses induce endothelial VCAM-1 
expression, leading to sickle cell adherence via the a4ll1 /vcAm-1 pathway. Last year 
we presented data that the synthetic double stranded RNA poly(I:C), induces 
endothelial VCAM-1 expression and that sickle erythrocytes adhere to poly(I:C) 
stimulated endothelium via a4 p 1 picAm-1 (7). Subsequent experiments have 
demonstrated that an intact double stranded RNA virus, parainfluenza 1 virus 
(Sendai), can also induce endothelial cell VCAM-1 expression leading to sickle cell 
adherence via a4131/VCAM-1 (Figure 1) similar to that induced by poly(I:C). 
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Figure 1. Adherence of sickle erythrocytes to endothelium 
infected with DS-RNA virus occurs via an ad1/vcA1-1 mediated 
mechanism Where indicated, endothelial cells were incubated 
with anti-VCAM-1 antibody (X-VCAM-1) or erythrocytes were 
incubated with anti-a4 antibody (X-a4). Data are meantSEM. 
Percent antibody blocking is indicated above the bars. Inset: 
Endothelial VCAM-1 expression was quantified by ELISA after a 
1 hr treatment of EC with Sendai virus and a 19 hr post-
infection culture period (right bar), a 20 hour EC treatment 
with poly(I:C) (middle bar), or no EC treatment (left bar).. 
Biophysical characterization of adherence pathways 
In addition to a401/vcAm-1, sickle cells adhere to endothelium via at least 
three other receptor-mediated pathways: (i) unusually large von Willebrand factor 
multimers bridging integrin and GPIb-like receptors on sickle cells and endothelium 
(2,3); (ii) thrombospondin-mediated adhesion via CD36 on sickle cells and CD36 or 
avO3 on microvascular endothelium (5) or a vO3 on umbilical vein endothelium (14), 
and (iii) phorbol ester activated a401 on sickle cells binding to fibronectin on 
endothelium (8). 
Thus, sickle erythrocyte adherence to endothelium in vivo is likely complex 
and can occur via multiple and different adherence pathways. 
In order to determine the conditions under which these pathways may dominate 
in vivo, we have initiated biophysical studies to compare the strength of sickle 
cell adherence via different pathways. In these studies, sickle cells are attached 
to endothelium under static conditions or at a shear stress of 0.5 or 1.0 dyne/cm 2 
 under conditions where only one adherence pathway is possible. Then, the 
hemodynamic shear stress is increased sequentially by 0.5 dyne/cm 2 increments. At 
each shear stress the number of adherent cells remaining is quantified. 
Even thought the initial attachment via the aj1/vCAM-1 and thrombospondin 
pathways were essentially equivalent at an attachment shear stress of 1.0 dyne/cm 2 , 
more sickle cells remained adherent at every shear stress for the a4131/vCAM-1 
pathway as compared to the thrombospondin pathway (Figure 2). This is especially 
evident when the data are normalized to the percentage of the cells initially 
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Figure 2. Sickle cell adherence as a function of 
wash-out shear stress. Sickle red cells were 
attached to the endothelium under a shear stress 
of 1.0 dyne/cm2 and washed off at sequentially 
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The conditions of sickle cell attachment also effect the number of sickle 
cells remaining adherent at subsequently higher shear stresses (Figures 4&5). In 
these experiments, sickle cells were flowed over endothelial cell monolayers 
stimulated with poly(I:C) (to induce VCAM-1 expression) at 0.5 or 1.0 dyne/cm2 shear 
stress or statically incubated with stimulated endothelium. Then, shear stress was 
increased in 0.5 dyne/cm 2 increments and sickle cell adherence was quantified. 
Initial sickle cell attachment was greatest at 0.5 dyne/cm 2 (Figure 4). However, as 
the wash-out shear stress was increased, the sickle cells adhered under 1 dyne/cm 2 
shear stress adhered most tenaciously (Figures 4&5). 
Figure 4. if fact of attachment shear stress on 
the tenacity of sickle cell adherence to 
endothelium via a01/VCAK-1. The three curves 
represent the number of red cells remaining 
adherent to endothelium at the indicated shear 
stress for sickle cells initially attached to the 
endothelium during a static incubation or at a 
shear stress of 0.5 or 1.0 dyne/cm 2 . 
3. 	Significance 
Figure 5. affect of attachment shear stress on 
the percent of sickle cells remaining adherent to 
endothelium via ae1/VCA•-1 as detachment 'shear 
stress is increased. 
The Role of Viral Infection in Sickle Cell Adherence 
The data of Figure 1 provides clear evidence that double stranded RNA or 
double stranded RNA viruses can induce endothelial cell VCAM-1 expression and sickle 
cell adherence via a401/VCAM-1. The clinical association of febrile events (15) with 
acute pain episodes in sickle cell patients suggests a role for infection in the 
development of vaso-occlusive pain episodes. Although research has focused on 
bacterial infection in sickle cell anemia (16,17), viral infection also appears to 
play a role in causing complications in sickle cell disease. During confirmed cases 
of infection by the RNA virus Influenza B, acute pain episode have been reported 
(18), and viral infections are thought to precipitate such complications as acute 
chest syndrome (19). Infection is known to activate certain leukocytes causing 
release of cytokines such as type I interferons and TNF -a, and leading to the 
development of an antiviral environment in the attacked host (20,21). Many sickle 
cell patients have been clinically observed to have consistently elevated cytokine 
levels (22). The release of these agents within the vascular system, specifically 
TNF -a, can lead to increased endothelial surface expression of cellular adhesion 
molecules, which are then thought to play a role in sickle erythrocyte-endothelial 
adhesion (6). Viral infection may therefore directly increase adherence through the 
effects of double stranded RNA on vascular endothelial cells and indirectly by 
leukocyte activation. Both of these pathways, induced by viral infection, may lead 
to an activated vascular state that favors high levels of sickle erythrocyte-
endothelial adherence and promotes vaso-occlusive complications. 
Biophysical Characterization of Sickle Adherence Pathways 
Adherence of sickle erythrocytes is complicated and modulated by receptors on 
sickle erythrocytes and endothelial cells; plasma proteins and blood-borne agonists; 
and local hemodynamic forces. At least four different adherence pathways have been 
identified (2,3,5,6,8,14) an adherence is different to large vessel and 
microvascular endothelium (4). 
It is possible that inhibition or reversal of sickle cell adherence to the 
endothelium could attenuate the ischemic tissue and organ damage associated with 
sickle cell pain episodes. However, the multiple and different adherence pathways 
of sickle cell adherence make it difficult to predict which pathway, if any, 
predominates in the vascular milieu. 
The parallel-plate flow chamber adherence assays we have utilized are uniquely 
suited to studies designed to compare the relative tenacity of competing adherence 
pathways. As shown in Figures 2-5, adherence between the two pathways studied to 
date (thrombospondin and a401/vcAm-1) demonstrate clear differences in the level of 
sickle cell adherence at sequentially increasing shear stress. Most notably, even 
though the initial attachment of sickle cells via thrombospondin or a401/VCAM - 1 is 
essentially equivalent, sickle cells attached to the endothelium via thrombospondin 
are more readily detached from the endothelium. In fact, at 4 dynes/cm 2 shear 
stress, essentially all of the sickle cells attached via thrombospondin are removed. 
In contrast, more than 15% of the cells attached via a4131/VCAM - 1 remain adherent at 
4 dynes/cm2 . Thus, not only do more sickle cells remain adherent at each shear 
stress via aal/WAM- 1, a significant fraction of these cells remain tenaciously 
adherent to the endothelium at a shear stress level that would be observed in the 
post-capillary venules. 
Biophysical characterizations of sickle cell adherence, such as those 
presented here, provide insights into the conditions under which sickle cell 
adherence via specific mechanisms occurs. These data, generated using human 
vascular endothelial cells under hemodynamic conditions which mimic those in vivo, 
will be useful in identifying the ability of specific pathways to promote adherence 
under a variety of vascular conditions that might arise in response to infection, 
thrombosis or other hematopoietic stresses which may increase the level or tenacity 
of sickle cell adherence. Then, with this more complete understanding of sickle 
cell adherence under a wide variety of conditions, effective anti-adhesion 
therapeutics can be more efficiently developed to inhibit or reverse sickle cell 
adherence and the attendant vascular complications. 
4. 	Plans 
Biophysical Characterization of Adherence Pathways - Strength of Adherence 
The data of Figures 2-5 suggest that differences in the tenacity of sickle 
cell adherence observed under shear conditions is mediated by specific receptors and 
ligands which are sensitive to kinetics (contact time), hemodynamic forces (shear 
stress), and available contact area (steric considerations). Our immediate plans 
are to characterize the tenacity of sickle cell adherence to endothelium via the 
other two adherence pathways (mediated by high molecular weight von Willebrand 
factor multimers bridging receptors on sickle erythrocytes and endothelial cells and 
sickle cell phorbol ester activated a401, binding to fibronectin on endothelial 
cells). Shear stress wash out curves will be generated as for the other two 
pathways (Fig 2,3) and the effect of attachment conditions on tenacity will be 
qualified (Fig 4,5). 
Note that the above experiments involve studying individual adherence pathways 
under isolated conditions. Thus, this initial series of experiments will indicate 
two things. First, by quantifying the number density of adherent red cells under 
otherwise identical conditions, the relative level of adherence via each pathway can 
be obtained. Secondly, the wash out curves indicate the pathway(s) which provide 
for the strongest sickle cell adherence. It is likely that both the absolute number 
of adherent cells and the tenacity of the adherence are important for clinically 
relevant adherence in vivo. 
Biophysical Characterization of Adherence Pathways - Kinetics of Adherence 
In conjunction with the detachment assays, which primarily provide data on the 
strength of sickle cell adherence, we plan to initiate studies to measure the rate 
(kinetics) of sickle cell adherence to endothelium via the various pathways. For 
these studies we have designed and constructed a cone-and-plate viscometer to be 
used to observe the kinetics of sickle cell attachment under varying conditions of 
activation. Figure 6 is a schematic diagram of our dynamic assay to measure red 
cell attachment kinetics. This system has been recently tested and can provide a 
constant and continuous shear stress for up to 48 hours without endothelial cell 
loss or contamination. Our experimental design will be to subject a suspension of 
sickle or normal erythrocytes to a shear stress in the range of 0.1 - 10 dynes/cm' 
and visually monitor and record the level of adherence to endothelium in response to 
manipulations of the biochemical or biophysical environment. For example, the 
injection ports allow for introduction of agonists (e.g. TNF - a, Poly(I:C), phorbol 
ester, etc.) and/or adhesive proteins (thrombospondin, von Willebrand factor). 
Then, the level of adherence in response to these manipulations will provide data on 
the kinetics via a specific pathway. These data will indicate the rate of sickle 
adherence induced by a specific alteration in the vascular milieu such as double 
stranded RNA virus infection, cytokine release, or high molecular weight von 
Willebrand factor release. More importantly, this system will be useful to test 
anti-adherence compounds (such as RGD peptides) for their ability to dislodge 
adherent cells in a flow environment. Thus, the attachment kinetics data will 
complement the strength of adherence data and provide a more complete picture of the 
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thermometer 
Pigure 6. Cone-and-plate apparatus to measure the kinetics of sickle cell 
adherence. Note that the injection ports allow for the circulation of 
agonists, adhesive proteins, or other effectors of cell adherence or 
disadherence. 
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5. Human Subjects 
a. General Guidelines 
i. Proposed Use 
Patients with sickle-cell syndromes (HbSS, HbSC, HbS P-thalassemia) not 
receiving anticoagulant therapy and without evidence of pregnancy, obvious 
infection, thromboembolic disease or liver disease will be eligible for this study. 
Patients will be studied once in pain crisis and twice during asymptomatic periods. 
An age and sex matched population of normal black individuals will serve as a 
control population. Approximately twenty patients and twenty control subjects, aged 
eighteen or older, will be studied annually. Ten milliliters of blood will be drawn 
by venipuncture for each experiment. 
ii. Specimen Usage 
None of the data from the experiments will be used for diagnosis or treatment 
of specific individuals. 
iii. Patient Recruitment 
Patients from the Georgia Comprehensive Sickle Cell Center or the in-patient 
service at Grady Memorial Hospital, Atlanta, GA and hospital staff will be recruited 
by Dr. James R. Eckman, M.D. Subjects will agree to participate in this study by 
signing a consent form approved by Georgia Tech and Emory University School of 
Medicine IRBs. The consent form explains the nature of the study, the details of 
blood collection, risks associated with drawing blood, the availability of personnel 
to discuss the results of the study, the assurance of anonymity, and the ability to 
withdraw from the study at any time without penalty or loss of benefits. 
iv. Potential Risks 
The risks of drawing blood are minimal and include slight pain, bruising, and 
infection at the site of puncture. No viable alternative for drawing human blood 
exists. 
v. Procedures to Minimize Risk 
Patient confidentiality is be ensured by assigning an alphanumeric code to 
each patient studied to be used when all data is reported. Blood will be drawn at 
Grady Hospital under the supervision of Dr. James R. Eckman, director of the Georgia 
Comprehensive Sickle Cell Center. Dr. Eckman will be available to answer questions 
and to arrange for emergency medical care if a medical problem develops during the 
course of this study. 
vi. Justification 
The risk of blood drawing is minimal compared to potential benefits of a 
better understanding of clotting abnormalities in sickle cell syndromes and their 
relationship to pain crisis. 
b. Gender and Minority Inclusions 
Study subjects will be patients diagnosed with sickle cell syndromes as defined 
above. These patients will primarily be of African descent, however no patients 
will be included or excluded on the basis of race. The study population will 
consist of approximately equal numbers of men and women. Exclusion criteria will be 
solely based on medical criteria as described above. Control subjects (volunteers 
without hemoglobinopathies) will be age, sex, and race-matched. These volunteers 
are recruited from the hospital staff at Grady Memorial Hospital in Atlanta. 
6. Vertebrate Animals 
None. 
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7. Inventions and Patents 
None. 
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